Anti–Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid Arthritis

Pharmacology, Toxicology and Pharmaceutical Science

• Rheumatoid Arthritis 100%
• Autoantibodies 100%
• Disease Duration 100%
• Protein Arginine Deiminase 83%
• Methotrexate 50%
• Adalimumab 16%
• Disease Activity Score 16%
• Tofacitinib 16%
• Disease 8%
• Prevalence 8%
• Randomized Clinical Trial 8%
• Remission 8%
• C Reactive Protein 8%
• Therapeutic Window 8%

Immunology and Microbiology

• Inflammatory Arthritis 100%
• Autoantibodies 100%
• Methotrexate 50%
• Monospecific Antibody 41%
• Adalimumab 16%
• Tofacitinib 16%
• Prevalence 8%
• Serology 8%
• C-Reactive Protein 8%
• Demography 8%

Keyphrases

• Early Duration 10%